J. Berrouschot

发表

Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial

H. Diener, C. Molina, H. Chabriat, 2020, The Lancet Neurology.

Long-term Cardiac Monitoring for Detection of Occult Atrial Fibrillation – A Tool to Prevent Secondary Stroke in Cryptogenic Stroke Patients

J. Berrouschot, 2014 .

Aspirin resistance in secondary stroke prevention

A. Siegemund, T. Siegemund, J. Berrouschot, 2006, Acta neurologica Scandinavica.

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma

J. Panse, M. Sabel, R. Fietkau, 2021, British Journal of Cancer.

Infection after Acute Ischemic Stroke: Risk Factors, Biomarkers, and Outcome

J. Schmidt, K. Wartenberg, A. Stoll, 2011, Stroke research and treatment.

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.

D. Tanné, D. Blacker, S. Connolly, 2018, The Lancet. Neurology.

Epilepsy outcomes in elderly treated with topiramate

H. Stefan, A. Schreiner, B. Schauble, 2008, Acta neurologica Scandinavica.

Effect of incomplete reperfusion patterns on clinical outcome: insights from the ESCAPE-NA1 trial

Thalia Shoshana Field, A. Demchuk, M. Tymianski, 2023, Journal of neurointerventional surgery.

An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial

H. Diener, M. Endres, C. Hobohm, 2019, The Lancet.

Epilepsy outcomes in elderly treated with topiramate

A. Schreiner, B. Kasper, I. Peglau, 2008, Acta neurologica Scandinavica.

Infection after Acute Ischemic Stroke: Risk Factors, Biomarkers, and Outcome

K. Wartenberg, A. Stoll, J. Berrouschot, 2011, Stroke research and treatment.